PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Prime Medicine, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.83+0.36 (+10.37%)
Close on Oct 19, 2026
- Market cap
- $678.77M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.62 (−29.72%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Prime Medicine, Inc. grew revenue 55.3% to $4.63M over fiscal 2025. Free cash flow was -$156.85M.
Revenue
$4.63M
+55.3% vs. a year earlier
Operating income
-$196.52M
TTM Q2 2026
Free cash flow
-$156.85M
TTM Q2 2026
EPS, diluted
-$1.10
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $678.77M
- P/E ratio
- –
- Price to sales
- 146.54
- Price to book
- 17.05
- Dividend yield
- –
- Free cash flow yield
- -23.11%
Fundamentals
- Revenue
- $4.63M
- Net income
- -$187.89M
- EPS, diluted
- -$1.10
- Free cash flow
- -$156.85M
- Book value per share
- $0.22
- Diluted shares
- 177M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$196.52M
Net income
-$187.89M
EPS, diluted
-$1.10
Free cash flow
-$156.85M
Reported periodTrailing twelve months